Skip to main content
This section contains press releases and other materials from third parties (including paid content). The Globe and Mail has not reviewed this content. Please see disclaimer.

Bank of America Securities Reaffirms Their Hold Rating on Biogen (BIIB)

Tipranks - Tipranks - Wed Feb 4, 6:10AM CST

In a report released today, Jason Zemansky from Bank of America Securities reiterated a Hold rating on Biogen, with a price target of $187.00.

Claim 50% Off TipRanks Premium

According to TipRanks, Zemansky is a 5-star analyst with an average return of 20.0% and a 59.60% success rate. Zemansky covers the Healthcare sector, focusing on stocks such as Cytokinetics, Madrigal Pharmaceuticals, and Kura Oncology.

In addition to Bank of America Securities, Biogen also received a Hold from Citi’s Geoff Meacham in a report issued on January 28. However, on January 30, Jefferies maintained a Buy rating on Biogen (NASDAQ: BIIB).

See Insiders’ Hot Stocks on TipRanks >>

Based on Biogen’s latest earnings release for the quarter ending September 30, the company reported a quarterly revenue of $2.45 billion and a net profit of $466.5 million. In comparison, last year the company earned a revenue of $2.47 billion and had a net profit of $388.5 million

Read More on BIIB:

Disclaimer & DisclosureReport an Issue

This article contains syndicated content. We have not reviewed, approved, or endorsed the content, and may receive compensation for placement of the content on this site. For more information please view the Barchart Disclosure Policy here.

All market data (will open in new tab) is provided by Barchart Solutions. Copyright © 2026.

Information is provided 'as is' and solely for informational purposes, not for trading purposes or advice. For exchange delays and terms of use, please read disclaimer (will open in new tab).